AU2020343329C1 - Methods of treatment - Google Patents

Methods of treatment

Info

Publication number
AU2020343329C1
AU2020343329C1 AU2020343329A AU2020343329A AU2020343329C1 AU 2020343329 C1 AU2020343329 C1 AU 2020343329C1 AU 2020343329 A AU2020343329 A AU 2020343329A AU 2020343329 A AU2020343329 A AU 2020343329A AU 2020343329 C1 AU2020343329 C1 AU 2020343329C1
Authority
AU
Australia
Prior art keywords
formula
substituted
alkyl
independently
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020343329A
Other languages
English (en)
Other versions
AU2020343329A1 (en
AU2020343329B2 (en
Inventor
Robert Davis
Peng Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2020343329A1 publication Critical patent/AU2020343329A1/en
Application granted granted Critical
Publication of AU2020343329B2 publication Critical patent/AU2020343329B2/en
Publication of AU2020343329C1 publication Critical patent/AU2020343329C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020343329A 2019-09-03 2020-09-03 Methods of treatment Active AU2020343329C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895476P 2019-09-03 2019-09-03
US62/895,476 2019-09-03
PCT/US2020/049248 WO2021046250A1 (en) 2019-09-03 2020-09-03 Methods of treatment

Publications (3)

Publication Number Publication Date
AU2020343329A1 AU2020343329A1 (en) 2022-03-24
AU2020343329B2 AU2020343329B2 (en) 2025-07-24
AU2020343329C1 true AU2020343329C1 (en) 2026-02-12

Family

ID=74853030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020343329A Active AU2020343329C1 (en) 2019-09-03 2020-09-03 Methods of treatment

Country Status (11)

Country Link
US (1) US12599603B2 (https=)
EP (1) EP4025218A4 (https=)
JP (1) JP7631319B2 (https=)
KR (1) KR20220054853A (https=)
CN (1) CN114340636A (https=)
AU (1) AU2020343329C1 (https=)
BR (1) BR112022003670A2 (https=)
CA (1) CA3147071A1 (https=)
IL (1) IL290983A (https=)
MX (1) MX2022002607A (https=)
WO (1) WO2021046250A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054853A (ko) 2019-09-03 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 치료 방법
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MA32942B1 (fr) * 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
JP6224597B2 (ja) 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) * 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
JP2018515474A (ja) 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
KR20180105685A (ko) * 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
EP3558319A4 (en) 2016-12-22 2020-07-22 AbbVie Inc. COMPOSITIONS AND PROCESSES FOR IMPROVING OR INCREASING THE PRODUCTION OF TYPE I IFN
EP3612839A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
TW201920104A (zh) 2017-08-31 2019-06-01 美商馬愈法瑪公司 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途
US20210338679A1 (en) 2018-09-25 2021-11-04 Intra-Cellular Therapies, Inc. Novel uses
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054853A (ko) 2019-09-03 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 치료 방법
MX2024010993A (es) 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHNSON, J.J. MUKHTAR, H.: "Curcumin for chemoprevention of colon cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 255, no. 2, 8 October 2007 (2007-10-08), US, pages 170 - 181, XP022208114, ISSN: 0304-3835, DOI: 10.1016/j.canlet.2007.03.005 *
PENG TING ET AL: "Inhibitors of phosphodiesterase as cancer therapeutics", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 150, 1 April 2018 (2018-04-01), AMSTERDAM, NL, pages 742 - 756, *
TAEKO HAYAKAWA ET AL: "Enhanced anti-tumor effects of the PD-1/PD-L1 blockade by combining a highly absorptive form of NF-kB/STAT3 inhibitor curcumin", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL, , vol. 2, no. Suppl 3, pages P210, *

Also Published As

Publication number Publication date
IL290983A (en) 2022-05-01
WO2021046250A1 (en) 2021-03-11
JP2022546711A (ja) 2022-11-07
JP7631319B2 (ja) 2025-02-18
AU2020343329A1 (en) 2022-03-24
US20220354851A1 (en) 2022-11-10
EP4025218A1 (en) 2022-07-13
BR112022003670A2 (pt) 2022-05-24
MX2022002607A (es) 2022-03-25
KR20220054853A (ko) 2022-05-03
CN114340636A (zh) 2022-04-12
CA3147071A1 (en) 2021-03-11
US12599603B2 (en) 2026-04-14
AU2020343329B2 (en) 2025-07-24
EP4025218A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
JP7564172B2 (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
US20250339438A1 (en) Organic compounds
AU2020343329C1 (en) Methods of treatment
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
US20250186446A1 (en) Organic compounds
RU2822394C1 (ru) Способы лечения
HK40066948A (zh) 治疗方法
CN118922191A (zh) 有机化合物
HK40112650A (zh) 有机化合物
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 OCT 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 OCT 2025

FGA Letters patent sealed or granted (standard patent)